Cargando…

Drug Discovery for Chagas Disease: Impact of Different Host Cell Lines on Assay Performance and Hit Compound Selection

Cell-based screening has become the major compound interrogation strategy in Chagas disease drug discovery. Several different cell lines have been deployed as host cells in screening assays. However, host cell characteristics and host-parasite interactions may play an important role when assessing a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Franco, Caio Haddad, Alcântara, Laura Maria, Chatelain, Eric, Freitas-Junior, Lucio, Moraes, Carolina Borsoi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6630705/ https://www.ncbi.nlm.nih.gov/pubmed/31108888 http://dx.doi.org/10.3390/tropicalmed4020082

Ejemplares similares

Nitroheterocyclic compounds are more efficacious than CYP51 inhibitors against Trypanosoma cruzi: implications for Chagas disease drug discovery and development
por: Moraes, Carolina B., et al.
Publicado: (2014)

A Multi-Species Phenotypic Screening Assay for Leishmaniasis Drug Discovery Shows That Active Compounds Display a High Degree of Species-Specificity
por: Alcântara, Laura M., et al.
Publicado: (2020)

The translational challenge in Chagas disease drug development
por: Kratz, Jadel M, et al.
Publicado: (2022)

Identification of Inhibitors to Trypanosoma cruzi Sirtuins Based on Compounds Developed to Human Enzymes
por: Matutino Bastos, Tanira, et al.
Publicado: (2020)

Human induced pluripotent stem cells as a tool for disease modeling and drug screening for COVID-19
por: Nolasco, Patricia, et al.
Publicado: (2020)

Rate-of-Kill (RoK) assays to triage large compound sets for Chagas disease drug discovery: Application to GSK Chagas Box
por: Cantizani, Juan, et al.
Publicado: (2021)

Synthetic Medicinal Chemistry in Chagas’ Disease: Compounds at The Final Stage of “Hit-To-Lead” Phase
por: Cerecetto, Hugo, et al.
Publicado: (2010)

Development of Trypanosoma cruzi in vitro assays to identify compounds suitable for progression in Chagas’ disease drug discovery
por: MacLean, Lorna M., et al.
Publicado: (2018)

Hits Discovery on the Androgen Receptor: In Silico Approaches to Identify Agonist Compounds
por: Réau, Manon, et al.
Publicado: (2019)

Live-imaging rate-of-kill compound profiling for Chagas disease drug discovery with a new automated high-content assay
por: Svensen, Nina, et al.
Publicado: (2021)

An Image-Based High-Content Screening Assay for Compounds Targeting Intracellular Leishmania donovani Amastigotes in Human Macrophages
por: Siqueira-Neto, Jair L., et al.
Publicado: (2012)

Carlos Chagas Discoveries as a Drop Back to Scientific Construction of Chronic Chagas Heart Disease
por: Bestetti, Reinaldo B., et al.
Publicado: (2016)

Chagas disease research and development: Is there light at the end of the tunnel?
por: Chatelain, Eric
Publicado: (2016)

Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity
por: Zingales, Bianca, et al.
Publicado: (2014)

Asteraceae Plants as Sources of Compounds Against Leishmaniasis and Chagas Disease
por: Moraes Neto, Roberval Nascimento, et al.
Publicado: (2019)

Development of a Fluorescence-based Trypanosoma cruzi CYP51 Inhibition Assay for Effective Compound Triaging in Drug Discovery Programmes for Chagas Disease
por: Riley, Jennifer, et al.
Publicado: (2015)

Amazonian Plant Natural Products: Perspectives for Discovery of New Antimalarial Drug Leads
por: Pohlit, Adrian Martin, et al.
Publicado: (2013)

Chagas Disease: From Discovery to a Worldwide Health Problem
por: Lidani, Kárita Cláudia Freitas, et al.
Publicado: (2019)

A note on the the discovery of Chagas' disease
por: de Avila-Pires, Fernando Dias
Publicado: (2022)

State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation
por: Gabaldón-Figueira, Juan Carlos, et al.
Publicado: (2023)

An Image-Based Algorithm for Precise and Accurate High Throughput Assessment of Drug Activity against the Human Parasite Trypanosoma cruzi
por: Moon, Seunghyun, et al.
Publicado: (2014)

Compound Prioritization through Meta-Analysis Enhances the Discovery of Antimicrobial Hits against Bacterial Pathogens
por: Deblais, Loic, et al.
Publicado: (2021)

Evaluation of the Chagas Western Blot IgG Assay for the Diagnosis of Chagas Disease
por: Brossas, Jean-Yves, et al.
Publicado: (2021)

Translational challenges of animal models in Chagas disease drug development: a review
por: Chatelain, Eric, et al.
Publicado: (2015)

A Static-Cidal Assay for Trypanosoma brucei to Aid Hit Prioritisation for Progression into Drug Discovery Programmes
por: De Rycker, Manu, et al.
Publicado: (2012)

Series of screening compounds with high hit rates for the exploration of multi-target activities and assay interference
por: Stumpfe, Dagmar, et al.
Publicado: (2018)

Discovery of Non-Peptidic Compounds against Chagas Disease Applying Pharmacophore Guided Molecular Modelling Approaches
por: Rampogu, Shailima, et al.
Publicado: (2018)

Discovery and optimisation studies of antimalarial phenotypic hits
por: Mital, Alka, et al.
Publicado: (2015)

Chagas Disease Treatment and Rational Drug Discovery: A Challenge That Remains
por: Silva, Ana Catarina Cristovão, et al.
Publicado: (2019)

Quantum dots: a new tool for anti-malarial drug assays
por: Ku, Min-Je, et al.
Publicado: (2011)

Identification of di-substituted ureas that prevent growth of trypanosomes through inhibition of translation initiation
por: Machado, Fabricio Castro, et al.
Publicado: (2018)

The Centennial of the Discovery of Chagas Disease: Facing the Current Challenges
por: Lannes-Vieira, Joseli, et al.
Publicado: (2010)

Discovery and Genetic Validation of Chemotherapeutic Targets for Chagas' Disease
por: Osorio-Méndez, Juan Felipe, et al.
Publicado: (2019)

Advances in preclinical approaches to Chagas disease drug discovery
por: Villalta, Fernando, et al.
Publicado: (2019)

Discovery of novel hit compounds with broad activity against visceral and cutaneous Leishmania species by comparative phenotypic screening
por: Lamotte, S., et al.
Publicado: (2019)

Discovery of a fragment hit compound targeting D-Ala:D-Ala ligase of bacterial peptidoglycan biosynthesis
por: Proj, Matic, et al.
Publicado: (2022)

Actin oligomers hit the assembly line
por: Short, Ben
Publicado: (2010)

Non-invasive monitoring of drug action: A new live in vitro assay design for Chagas’ disease drug discovery
por: Fesser, Anna F., et al.
Publicado: (2020)

Robust Strategy for Hit-to-Lead Discovery: NMR for SAR
por: Larda, Sacha T., et al.
Publicado: (2023)

2-aminobenzimidazoles for leishmaniasis: From initial hit discovery to in vivo profiling
por: Ferreira, Rafael Augusto Alves, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ikhjem5ltojia9m1ppm1548tb4